Literature DB >> 11730736

Male partner screening before in vitro fertilization: preselecting patients who require intracytoplasmic sperm injection with the sperm penetration assay.

M R Freeman1, A E Archibong, J J Mrotek, C M Whitworth, G A Weitzman, G A Hill.   

Abstract

OBJECTIVES: To determine the diagnostic accuracy of the sperm penetration assay (SPA) and standard semen parameters for subsequent fertilization in in vitro fertilization-embryo transfer (IVF-ET).
DESIGN: Prospective study.
SETTING: Andrology Laboratory, and university research laboratory. PATIENTS: Two hundred sixteen couples undergoing male-partner screening before IVF-ET (265 cycles). INTERVENTION(S): Male-partner screening (semen analyses [SA] and SPA), standard IVF-ET procedures, follow-up of fertilization in IVF-ET. MAIN OUTCOME MEASURE(S): Diagnostic accuracy of SA and SPA for prediction of fertilization in IVF-ET. RESULT(S): The SPA predicted IVF fertilization with high negative (84%) and positive (98%) predictive rates, and correct prediction in 88% of cycles. In contrast, sperm concentration, motility, morphology, and complete SA showed poor diagnostic accuracy, with correct prediction of IVF fertilization in 64%, 65%, 45%, and 68% of cycles, respectively. CONCLUSION(S): Very low sperm concentration and/or motility were good predictors of poor IVF fertilization, however, low to normal semen parameters were not predictive of successful IVF fertilization. The SPA is a useful screening tool that predicts IVF fertilization with high diagnostic accuracy. The SPA may be useful to discriminate between those couples with a high probability of normal fertilization in IVF and those with a low probability of normal fertilization that may benefit from assisted fertilization by intracytoplasmic sperm injection (ICSI).

Entities:  

Mesh:

Year:  2001        PMID: 11730736     DOI: 10.1016/s0015-0282(01)02890-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

Review 1.  A translational medicine appraisal of specialized andrology testing in unexplained male infertility.

Authors:  Sandro C Esteves; Rakesh K Sharma; Jaime Gosálvez; Ashok Agarwal
Journal:  Int Urol Nephrol       Date:  2014-04-27       Impact factor: 2.370

Review 2.  Sperm function and assisted reproduction technology.

Authors:  Ralf Henkel; Gesa MAAß; Rolf-Hasso Bödeker; Christine Scheibelhut; Thomas Stalf; Claas Mehnert; Hans-Christian Schuppe; Andreas Jung; Wolf-Bernhard Schill
Journal:  Reprod Med Biol       Date:  2005-03-07

3.  The sperm penetration assay for the assessment of fertilization capacity.

Authors:  Kathleen Hwang; Dolores J Lamb
Journal:  Methods Mol Biol       Date:  2013

4.  Hyaluronan binding assay (HBA) vs. sperm penetration assay (SPA): Can HBA replace the SPA test in male partner screening before in vitro fertilization?

Authors:  Jelena Lazarevic; Maria Wikarczuk; Stephen G Somkuti; Larry I Barmat; Jay S Schinfeld; Scott E Smith
Journal:  J Exp Clin Assist Reprod       Date:  2010-02-10

Review 5.  Hemizona assay and sperm penetration assay in the prediction of IVF outcome: a systematic review.

Authors:  Paraskevi Vogiatzi; Charalampos Chrelias; David J Cahill; Maria Creatsa; Nikos Vrachnis; Zoe Iliodromiti; Demetrios Kassanos; Charalampos Siristatidis
Journal:  Biomed Res Int       Date:  2013-10-21       Impact factor: 3.411

6.  The hamster egg penetration test may decrease intracytoplasmic sperm injection utilization while maintaining high conventional fertilization rates.

Authors:  Yetunde Ibrahim; Brett Einerson; Douglas T Carrell; Benjamin R Emery; Erica Johnstone
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

7.  Semen molecular and cellular features: these parameters can reliably predict subsequent ART outcome in a goat model.

Authors:  Fiammetta Berlinguer; Manuela Madeddu; Valeria Pasciu; Sara Succu; Antonio Spezzigu; Valentina Satta; Paolo Mereu; Giovanni G Leoni; Salvatore Naitana
Journal:  Reprod Biol Endocrinol       Date:  2009-11-09       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.